Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP530755.RAbk7wmRvWUfN1-bUDhFfgPki_Pw1DyJeptYgZ2wOJ5zc130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP530755.RAbk7wmRvWUfN1-bUDhFfgPki_Pw1DyJeptYgZ2wOJ5zc130_assertion type Assertion NP530755.RAbk7wmRvWUfN1-bUDhFfgPki_Pw1DyJeptYgZ2wOJ5zc130_head.
- NP530755.RAbk7wmRvWUfN1-bUDhFfgPki_Pw1DyJeptYgZ2wOJ5zc130_assertion description "[Although patients who were found to have LOI of IGF2 were more likely to have advanced stage gastric tumors (P?=?0.04), no statistically significant differences in survival were found based on imprinting status.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP530755.RAbk7wmRvWUfN1-bUDhFfgPki_Pw1DyJeptYgZ2wOJ5zc130_provenance.
- NP530755.RAbk7wmRvWUfN1-bUDhFfgPki_Pw1DyJeptYgZ2wOJ5zc130_assertion evidence source_evidence_literature NP530755.RAbk7wmRvWUfN1-bUDhFfgPki_Pw1DyJeptYgZ2wOJ5zc130_provenance.
- NP530755.RAbk7wmRvWUfN1-bUDhFfgPki_Pw1DyJeptYgZ2wOJ5zc130_assertion SIO_000772 21268128 NP530755.RAbk7wmRvWUfN1-bUDhFfgPki_Pw1DyJeptYgZ2wOJ5zc130_provenance.
- NP530755.RAbk7wmRvWUfN1-bUDhFfgPki_Pw1DyJeptYgZ2wOJ5zc130_assertion wasDerivedFrom befree-20140225 NP530755.RAbk7wmRvWUfN1-bUDhFfgPki_Pw1DyJeptYgZ2wOJ5zc130_provenance.
- NP530755.RAbk7wmRvWUfN1-bUDhFfgPki_Pw1DyJeptYgZ2wOJ5zc130_assertion wasGeneratedBy ECO_0000203 NP530755.RAbk7wmRvWUfN1-bUDhFfgPki_Pw1DyJeptYgZ2wOJ5zc130_provenance.